<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290092</url>
  </required_header>
  <id_info>
    <org_study_id>OLIVIER-FAIVRE ROCHE 2016</org_study_id>
    <nct_id>NCT03290092</nct_id>
  </id_info>
  <brief_title>Trial of Taselisib in Overgrowth</brief_title>
  <acronym>TOTEM</acronym>
  <official_title>A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Segmental overgrowth disorders are rare conditions characterised by abnormal growth which is&#xD;
      usually asymmetric and confined to discrete parts of the body. We and others have identified&#xD;
      mosaic activating mutations in the p110α catalytic subunit of phosphatidylinositol-3-kinase&#xD;
      (PI3K; encoded by the PIK3CA gene) in a subset of overgrowth disorders. The PI3K-AKT-mTOR is&#xD;
      a critical signalling pathway, which regulates cellular growth, proliferation and survival.&#xD;
      Activating mutations in PIK3CA lead to increased activation of the PI3K-AKT-mTORC1 axis,&#xD;
      which in turn promotes excessive growth in affected tissue.&#xD;
&#xD;
      The PIK3CA-related overgrowth spectrum is wide, and depends upon the timing of the founder&#xD;
      mutation in embryogenesis, and potentially upon the exact mutation. Clinical presentation&#xD;
      ranges from isolated enlargement of a digit, to extensive overgrowth of limbs, abdomen and in&#xD;
      some cases the brain, and may be accompanied by vascular or lymphatic malformations.&#xD;
      Associated morbidity can be profound, with functional impairment, debilitating haemorrhages&#xD;
      and thromboses, coupled with neurological sequelae and, in some cases, death. At present,&#xD;
      serial debulking surgery is the only available therapeutic option.&#xD;
&#xD;
      The identification of gain-of-function mutations in PI3K has raised the possibility of&#xD;
      treatment with drugs that inhibit PIK3CA (the p110 alpha catalytic subunit of PI3K).&#xD;
      Taselisib is a selective inhibitor of class I PI3Ks and has direct inhibitory activity of the&#xD;
      p110α isoform with a Kiapp value of 0.29 nmol/l.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    In accordance with the protocol, following the occurrence of two SUSARs, the TOTEM trial was&#xD;
    stopped early for safety reasons.&#xD;
  </why_stopped>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicities</measure>
    <time_frame>less than 24 hours</time_frame>
    <description>The dose limiting toxicity (DLT) is defined as a Grade 3 or more AE using the National Cancer Institute (NCI).&#xD;
If two out of up to six participants at the same dose level experience a DLT as defined above, subsequent cohorts will be dosed at a lower level as illustrated in the flow-chart below. At least six evaluable participants are required to establish the MTD (Maximum tolerated dose) at a specific dose level for both combinations.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>PIK3CA-Related Overgrowth</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taselisib (GDC0032)</intervention_name>
    <description>The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taselisib (GDC0032)</intervention_name>
    <description>The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given, or their legal representative has given, written informed consent to&#xD;
             participate&#xD;
&#xD;
          -  Aged 16 years to 65 years inclusive&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Post-zygotic PIK3CA mutation&#xD;
&#xD;
          -  Clinically stable in the opinion of the investigator&#xD;
&#xD;
          -  Participant Pregnancy and contraception:&#xD;
&#xD;
             o Female participants of child bearing potential must use an effective method of&#xD;
             contraception during treatment and for at least 3 months after the final dose of&#xD;
             taselisib. Acceptable methods are:&#xD;
&#xD;
          -  True abstinence (this must be the participant's usual and preferred lifestyle, not&#xD;
             just for the duration of the trial)&#xD;
&#xD;
          -  Oral contraceptive (either combined or progestogen alone)&#xD;
&#xD;
          -  Contraceptive implant, injections or patches&#xD;
&#xD;
          -  Vaginal ring&#xD;
&#xD;
          -  Intrauterine device (IUD, coil or intrauterine system)&#xD;
&#xD;
          -  Condom and cap&#xD;
&#xD;
          -  Diaphragm plus spermicide&#xD;
&#xD;
               -  A female participant of child bearing potential is defined as a sexually mature&#xD;
                  woman not surgically sterilized or not post-menopausal for at least 12&#xD;
                  consecutive months if aged 55 years or older.&#xD;
&#xD;
               -  Men must use one of the following, reliable forms to contraception for the entire&#xD;
                  duration of treatment and for 3 months after the final dose of taselisib:&#xD;
&#xD;
          -  Condom plus spermicide even if female partner is using another method of contraception&#xD;
             (Men should also use a condom to protect male partners, or female partners who are&#xD;
             pregnant or breast feeding, from exposure to the Trial medicine in semen).&#xD;
&#xD;
          -  True abstinence (this must be the participant's usual and preferred lifestyle, not&#xD;
             just for the duration of the Trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Hypersensitivity to taselisib or any of its excipients&#xD;
&#xD;
          -  Any current medical disorder or medication likely to impair ability to follow the&#xD;
             trial protocol safely and effectively&#xD;
&#xD;
          -  Are concurrently taking an mTOR inhibitor or any other small molecule inhibitor of the&#xD;
             PI3K-AKT signalling pathway&#xD;
&#xD;
          -  Unable or unwilling to give informed consent&#xD;
&#xD;
          -  Sirolimus or taselisib treatment in 12 weeks prior to screening&#xD;
&#xD;
          -  Treatment with a strong inducer or inhibitor of CYP3A4 without the possibility to stop&#xD;
             this medication within the week prior to the screening. This includes:&#xD;
&#xD;
          -  Macrolide Antibiotics: clarithromycin, telithromycin, erythromycin, troleandomycin&#xD;
&#xD;
          -  Gastrointestinal prokinetic agents: metoclopramide.&#xD;
&#xD;
          -  Antifungals: itraconazole, ketoconazole, fluconazole, voriconazole, clotrimazole&#xD;
&#xD;
          -  Calcium channel blockers: verapamil, diltiazem, nicardipine&#xD;
&#xD;
          -  Grapefruit containing foods/drinks&#xD;
&#xD;
          -  Anticonvulsants: carbamazepine, phenobarbital, phenytoin&#xD;
&#xD;
          -  Antibiotics: rifampicin, rifabutin, rifapentine&#xD;
&#xD;
          -  Herbal preparations: St. John's wort (Hypericum perforatum). Other drugs:&#xD;
             bromocriptine, cimetidine, danazol, cyclosporine, lansoprazole, calcium containing&#xD;
             antacids.&#xD;
&#xD;
          -  Inability to attend trial visits&#xD;
&#xD;
          -  If less than 3 months post- major surgery at screening&#xD;
&#xD;
          -  Any past medical history of inflammatory bowel disease or chronic diarrhoea of unknown&#xD;
             aetiology&#xD;
&#xD;
          -  History of type 1 or type 2 diabetes mellitus requiring insulin, GLP-1 analogues or&#xD;
             oral hypoglycaemic agents.&#xD;
&#xD;
          -  History of inflammatory bowel disease, ischemic colitis, or colitis of unknown origin.&#xD;
&#xD;
          -  Fasting blood glucose &gt; 6.9 mmol/l&#xD;
&#xD;
          -  HbA1C &gt; 6%&#xD;
&#xD;
          -  Long QT, congenital or acquired&#xD;
&#xD;
          -  Active pneumonitis&#xD;
&#xD;
          -  Patients who require daily supplemental oxygen&#xD;
&#xD;
          -  Inadequate renal function defined as creatinine clearance or radioisotope GFR &lt;&#xD;
             60ml/min/1.73 m²&#xD;
&#xD;
          -  Inadequate liver function defined as:&#xD;
&#xD;
          -  Total bilirubin &gt; 2.0 x ULN or conjugated bilirubin &gt; 2.0 x ULN for age, and&#xD;
&#xD;
          -  SGPT (ALT) or SGOT (AST) ≥ 1.5 x ULN for age, and&#xD;
&#xD;
          -  Serum albumin &lt; 30 g/L&#xD;
&#xD;
          -  Inadequate fasting LDL cholesterol &gt; 4.2 mmol/l&#xD;
&#xD;
          -  Deprived of freedom by an administrative or court order, or benefiting from a system&#xD;
             of legal protection (tutorship, curatorship or safeguard of justice).&#xD;
&#xD;
          -  Not covered by health insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - GH Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré (AP-HP)</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital femme-mère-enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion - Site GHSR</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne Hôpital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

